July 11, 2020 / 10:44 AM / a month ago

BRIEF-India's Biocon Says Itolizumab Receives DGCI Approval For Use In Moderate To Severe COVID-19 Patients

July 11 (Reuters) - Biocon Ltd:

* SAYS DRUG ITOLIZUMAB RECEIVES DRUGS CONTROLLER GENERAL OF INDIA’S APPROVAL FOR ITS USE IN MODERATE TO SEVERE COVID-19 PATIENTS

* BIOCON SAYS ITOLIZUMAB WILL BE MANUFACTURED AND FORMULATED AS AN INTRAVENOUS INJECTION AT CO’S BIO-MANUFACTURING FACILITY IN BENGALURU, INDIA Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below